Zelboraf FDA Approval History
FDA Approved: Yes (First approved August 17, 2011)
Brand name: Zelboraf
Generic name: vemurafenib
Dosage form: Tablets
Company: Genentech, Inc.
Treatment for: Melanoma, Metastatic
Zelboraf (vemurafenib) is a kinase inhibitor indicated for the treatment of patients with metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test, and for the treatment of patients with Erdheim-Chester Disease with BRAF V600 mutation.
Development timeline for Zelboraf
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.